Biosensors: The new wave in cancer diagnosis

Nanotechnology, Science and Applications

Volumn 4, Issue 1, 2011, Pages 1-10

  Bohunicky, Brian ^a   Mousa, Shaker A ^a,b  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Biosensor; Biotechnology; Cancer detection; Diagnosis; Nanotechnology; Oncogene; Point of care

Indexed keywords

CA 125 ANTIGEN; CA 15-3 ANTIGEN; CANCER TESTIS ANTIGEN; ENZYME; NANOPARTICLE; NUCLEIC ACID; PROSTATE SPECIFIC ANTIGEN; QUANTUM DOT; RECEPTOR BINDING CANCER ANTIGEN; RECEPTOR PROTEIN; SINGLE WALLED NANOTUBE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

AMPEROMETRIC BIOSENSOR; ANTIGEN ANTIBODY REACTION; BIOMEDICAL TECHNOLOGY ASSESSMENT; BIOSENSOR; CALORIMETRY; CANCER DIAGNOSIS; DIAGNOSTIC IMAGING; EARLY DIAGNOSIS; ELECTROCHEMICAL DETECTION; ENZYMIC BIOSENSOR; HUMAN; LAB ON A CHIP; MOLECULAR RECOGNITION; NANOTECHNOLOGY; NEOPLASM; OPTICAL BIOSENSOR; PIEZOELECTRICITY; PROTEOMICS; REVIEW; TRANSDUCER;

EID: 79952915579     PISSN: None     EISSN: 11778903     Source Type: Journal    
DOI: 10.2147/NSA.S13465     Document Type: Review

References (67)

1. Rasooly A, Jacobson J. Development of biosensors for cancer clinical testing. Biosens Bioelectron. 2006;21(10):1851-1858
2. Hu Y. BRCA1, hormone, and tissue-specific tumor suppression. Int J Biol Sci. 2009;5(1):20-27
3. EMORY University. Additional tumor suppressors. 2008. Available from: http://www.cancerquest.org/index.cfm?page=781. Accessed Sep 24 2010.
4. Fabregat I. Dysregulation of apoptosis in hepatocellular carcinoma cells. World J Gastroenterol. 2009;15(5):513-520
5. American Cancer Society. Oncogenes and tumor suppressor genes. 2005. Available from: http://www.cancer.org/docroot/ETO/content/ETO_1_4x_oncogenes_and_tumor_suppressor_genes.asp. Accessed Sep 24 2010.
6. Gown AM. Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol. 2008;21 Suppl 2:S8-S15.
7. King MW. Growth factors. 2009. Available from: http://themedicalbiochemistrypage.org/growth-factors.html. Accessed Sep 24 2010.
8. Farrell WE, Clayton RN. Epigenetic change in pituitary tumorigenesis. Endocr Relat Cancer. 2003;10(2):323-330
9. Stirzaker C, Millar DS, Paul CL, et al. Extensive DNA methylation spanning the Rb promoter in retinoblastoma tumors. Cancer Res. 1997; 57(11):2229-2237
10. Greger V, Debus N, Lohmann D, Hopping W, Passarge E, Horsthemke B. Frequency and parental origin of hypermethylated RB1 alleles in retinoblastoma. Hum Genet. 1994;94(5):491-496
11. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998;62(3):676-689
12. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266:66-71
13. Falette N, Paperin MP, Treilleux I, et al. Prognostic value of P53 gene mutations in a large series of node-negative breast cancer patients. Cancer Res. 1998;58(7):1451-1455
14. NCI. Biomarker. 2009. Available from: http://www.cancer.gov/dictionary/?searchTxt=biomarker. Accessed Sep 24 2010.
15. Basil CF, Zhao Y, Zavaglia K, et al. Common cancer biomarkers. Cancer Res. 2006;66(6):2953-2961
16. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on 1996 May 17 by the American Society of Clinical Oncology. J Clin Oncol. 1996;14(10):2843-2877
17. Tothill IE. Biosensors for cancer markers diagnosis. Semin Cell Dev Biol. 2009;20(1):55-62
18. Smith DS, Humphrey PA, Catalona WJ. The early detection of prostate carcinoma with prostate specific antigen: the Washington University experience. Cancer. 1997;80(9):1852-1856
19. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005; 352(19):1977-1984
20. NCI. Prostate specific antigen (PSA) test. 2009. Available from: http://www.cancer.gov/cancertopics/factsheet/detection/PSA. Accessed Sep 24 2010.
21. Thompson IM, Ankerst DP. Prostate-specific antigen in the early detection of prostate cancer. CMAJ. 2007;176(13):1853-1858
22. Meyer T, Rustin GJ. Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer. 2000;82(9):1535-1538
23. Tuxen MK, Soletormos G, Dombernowsky P. Tumor markers in the management of patients with ovarian cancer. Cancer Treat Rev. 1995; 21(3):215-245
24. Neesham D. Ovarian cancer screening. Aust Fam Physician. 2007; 36(3):126-128
25. Kui Wong N, Easton RL, Panico M, et al. Characterization of the oligosaccharides associated with the human ovarian tumor marker CA 125. J Biol Chem. 2003;278(31):28619-28634
26. Seelenmeyer C, Wegehingel S, Lechner J, Nickel W. The cancer antigen CA 125 represents a novel counter receptor for galectin-1. J Cell Sci. 2003;116(Pt 7):1305-1318
27. Duffy MJ. Serum tumor markers in breast cancer: are they of clinical value? Clin Chem. 2006;52(3):345-351
28. Tampellini M, Berruti A, Gerbino A, et al. Relationship between CA 15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease. Br J Cancer. 1997;75(5):698-702
29. Bast RC Jr, Ravdin P, Hayes DF, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19(6):1865-1878
30. Jager E, Stockert E, Zidianakis Z, et al. Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events. Int J Cancer. 1999;84(5):506-510
31. Kubokawa M, Nakashima M, Yao T, et al. Aberrant intracellular localization of RCAS1 is associated with tumor progression of gastric cancer. Int J Oncol. 2001;19(4):695-700
32. Dutsch-Wicherek M, Tomaszewska R, Lazar A, Wicherek L, Skladzien J. The association between RCAS1 expression in laryngeal and pharyngeal cancer and its healthy stroma with cancer relapse. BMC Cancer. 2009;9:35.
33. Alaoui-Jamali MA, Xu YJ. Proteomic technology for biomarker profiling in cancer: an update. J Zhejiang Univ Sci B. 2006;7(6):411-420
34. Hanash SM, Pitteri SJ, Faca VM. Mining the plasma proteome for cancer biomarkers. Nature. 2008;452(7187):571-579
35. Simpson KL, Whetton AD, Dive C. Quantitative mass spectrometrybased techniques for clinical use: biomarker identification and quantification. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877(13): 1240-1249
36. Wong SC, Chan CM, Ma BB, et al. Advanced proteomic technologies for cancer biomarker discovery. Expert Rev Proteomics. 2009;6(2): 123-134
37. Chaplin M. What are biosensors? 2004. Available from: http://www.lsbu.ac.uk/biology/enztech/biosensors.html. Accessed Sep 24 2010.
38. Chambers JP, Arulanandam BP, Matta LL, Weis A, Valdes JJ. Biosensor recognition elements. Curr Issues Mol Biol. 2008;10(1-2):1-12
39. Hirsch LR, Jackson JB, Lee A, Halas NJ, West JL. A whole blood immunoassay using gold nanoshells. Anal Chem. 2003;75(10): 2377-2381
40. Wu G, Ji H, Hansen K, et al. Origin of nanomechanical cantilever motion generated from biomolecular interactions. Proc Natl Acad Sci U S A. 2001;98(4):1560-1564
41. O'Connell PJ, Guilbault GG. Future trends in biosensor research. Anal Lett. 2001;34(7):1063-1078
42. Chen YT, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A. 1997;94(5):1914-1918
43. Jager D, Stockert E, Gure AO, et al. Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library. Cancer Res. 2001;61(5):2055-2061
44. Parker S, Lim Y, Lee D, et al. Identification and characterisation of a novel cancer/testis antigen gene CAGE-1. Biochim Biophys Acta. 2003; 1625(2):173-182
45. Tothill IE, Turner APF. Bionsensors. In: Caballero B, Trugo L, Finglas P, editors. Encyclopedia of Food Sciences and Nutrition. New York, NY: Academic Press; 2003:489-499
46. Jia Y, Qin M, Zhang H, et al. Label-free biosensor: a novel phage- modified Light Addressable Potentiometric Sensor system for cancer cell monitoring. Biosens Bioelectron. 2007;22(12):3261-3266
47. Wang J. Electrochemical biosensors: towards point-of-care cancer diagnostics. Biosens Bioelectron. 2006;21(10):1887-1892
48. Mikkelsen SR. Electrochemical biosensors for DNA sequence detection. Electroanalysis. 1996;8(1):15-19
49. Gooding JJ. Electrochemical sensors for DNA interactions and damage. Electroanalysis. 2002;14:1149-1156
50. Wang J, Kawde A-N. Pencil-based renewable biosensor for label-free electrochemical detection of DNA hybridization. Anal Chim Acta. 2001; 431(2):219-224
51. Koschwanez HE, Reichert WM. In vitro, in vivo and post explantation testing of glucose-detecting biosensors: current methods and recommendations. Biomaterials. 2007;28(25):3687-3703
52. Tamada JA, Garg S, Jovanovic L, Pitzer KR, Fermi S, Potts RO. Noninvasive glucose monitoring: comprehensive clinical results. Cygnus Research Team. JAMA. 1999;282(19):1839-1844
53. Asphahani F, Zhang M. Cellular impedance biosensors for drug screening and toxin detection. Analyst. 2007;132(9):835-841
54. Chan LL, Gosangari SL, Watkin KL, Cunningham BT. A label-free photonic crystal biosensor imaging method for detection of cancer cell cytotoxicity and proliferation. Apoptosis. 2007;12:1061-1068
55. Jacobson KB. Biosensors and other medical and environmental probes. Available from: http://www.ornl.gov/info/ornlreview/rev29_3/text/biosens.htm. Accessed Sep 24 2010.
56. Dell'Atti D, Tombelli S, Minunni M, Mascini M. Detection of clinically relevant point mutations by a novel piezoelectric biosensor. Biosens Bioelectron. 2006;21(10):1876-1879
57. Medley CD, Smith JE, Tang Z, Wu Y, Bamrungsap S, Tan W. Gold nanoparticle-based colorimetric assay for the direct detection of cancerous cells. Anal Chem. 2008;80(4):1067-1072
58. Grodzinski P, Silver M, Molnar LK. Nanotechnology for cancer diagnostics: promises and challenges. Expert Rev Mol Diagn. 2006; 6(3):307-318
59. Banerjee HN, Verma M. Use of nanotechnology for the development of novel cancer biomarkers. Expert Rev Mol Diagn. 2006;6(5):679-683
60. Zhang GJ, Chua JH, Chee RE, Agarwal A, Wong SM. Label-free direct detection of MiRNAs with silicon nanowire biosensors. Biosens Bioelectron. 2009;24(8):2504-2508
61. Wang J. Carbon-nanotube based electrochemical biosensors: a review. Electroanalysis. 2005;17:7-14
62. Cai H, Cao X, Jiang Y, He P, Fang Y. Carbon nanotube-enhanced electrochemical DNA biosensor for DNA hybridization detection. Anal Bioanal Chem. 2003;375(2):287-293
63. Yu X, Munge B, Patel V, et al. Carbon nanotube amplification strategies for highly sensitive immunodetection of cancer biomarkers. J Am Chem Soc. 2006;128(34):11199-11205
64. Jain KK. Applications of nanobiotechnology in clinical diagnostics. Clin Chem. 2007;53(11):2002-2009
65. Howarth M, Takao K, Hayashi Y, Ting AY. Targeting quantum dots to surface proteins in living cells with biotin ligase. Proc Natl Acad Sci U S A. 2005;102(21):7583-7588
66. Bharali DJ, Khalil M, Gurbuz M, Simone TM, Mousa SA. Nanoparticles and cancer therapy: a concise review with emphasis on dendrimers. Int J Nanomedicine. 2009;4:1-7
67. Moving biosensors to point-of-care cancer diagnostics. Proceedings of a symposium. 2005 Jun. Biosens Bioelectron. 2006;21(10):1847-1942